CA2319542C - Traitement des troubles de la sexualite chez certains groupes de patients - Google Patents

Traitement des troubles de la sexualite chez certains groupes de patients Download PDF

Info

Publication number
CA2319542C
CA2319542C CA002319542A CA2319542A CA2319542C CA 2319542 C CA2319542 C CA 2319542C CA 002319542 A CA002319542 A CA 002319542A CA 2319542 A CA2319542 A CA 2319542A CA 2319542 C CA2319542 C CA 2319542C
Authority
CA
Canada
Prior art keywords
flosequinan
subject
administration
quinolone
erection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002319542A
Other languages
English (en)
Other versions
CA2319542A1 (fr
Inventor
Neal R. Cutler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/071,457 external-priority patent/US6110489A/en
Priority claimed from US09/166,703 external-priority patent/US6194433B1/en
Priority claimed from US09/175,395 external-priority patent/US6132753A/en
Priority claimed from US09/260,099 external-priority patent/US6132757A/en
Priority claimed from US09/262,715 external-priority patent/US6187790B1/en
Application filed by Individual filed Critical Individual
Publication of CA2319542A1 publication Critical patent/CA2319542A1/fr
Application granted granted Critical
Publication of CA2319542C publication Critical patent/CA2319542C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)

Abstract

L'invention concerne des procédés de traitement des troubles de la sexualité chez certains groupes de patients. Ces procédés consistent à administrer des compositions pharmaceutiques à des patients ne présentant pas de maladie cardiaque et/ou auxquels on n'a pas administré de nitrates organiques.
CA002319542A 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients Expired - Fee Related CA2319542C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US09/071,457 US6110489A (en) 1998-05-01 1998-05-01 Use of quinolines and quinolones to treat male erectile dysfunction
US09/071,457 1998-05-01
US09/166,703 US6194433B1 (en) 1998-10-05 1998-10-05 Sexual dysfunction in females
US09/166,703 1998-10-05
US09/175,395 1998-10-19
US09/175,395 US6132753A (en) 1998-05-01 1998-10-19 Treatment of sexual dysfunction in certain patient groups
US09/260,099 1999-03-02
US09/260,099 US6132757A (en) 1998-05-01 1999-03-02 Treatment of sexual dysfunction in certain patient groups
US09/262,715 1999-03-04
US09/262,715 US6187790B1 (en) 1999-03-04 1999-03-04 Use of cilostazol for treatment of sexual dysfunction
PCT/US1999/009610 WO1999056666A1 (fr) 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients

Publications (2)

Publication Number Publication Date
CA2319542A1 CA2319542A1 (fr) 1999-11-11
CA2319542C true CA2319542C (fr) 2005-07-12

Family

ID=27535884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319542A Expired - Fee Related CA2319542C (fr) 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients

Country Status (7)

Country Link
EP (1) EP1079764A4 (fr)
JP (1) JP2002537231A (fr)
AU (1) AU3780699A (fr)
BR (1) BR9908716A (fr)
CA (1) CA2319542C (fr)
MX (1) MXPA00010254A (fr)
WO (1) WO1999056666A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6541487B1 (en) 1998-05-01 2003-04-01 R.T. Alamo Ventures I, Llc PDE III inhibitors for treating sexual dysfunction
CA2435876A1 (fr) * 2001-01-26 2002-08-01 R.T. Alamo Ventures I, Llc Traitement de troubles sexuels et de maladie cardio-vasculaire avec des enantiomeres quinolinone
US6727262B2 (en) 2002-03-01 2004-04-27 R.T. Alamo Ventures I, Llc Dichlorinated heterocyclic compounds and methods of synthesis
US6767914B2 (en) 2002-03-01 2004-07-27 R.T. Alamo Ventures I, Llc Fluorinated heterocyclic compounds and methods of synthesis
US7041677B2 (en) 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US6730790B2 (en) 2002-03-01 2004-05-04 R.T. Alamo Ventures I. Llc Chlorinated heterocyclic compounds and methods of synthesis
GB0208704D0 (en) * 2002-04-16 2002-05-29 Futura Medical Dev Ltd Condom
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
EP0651640A1 (fr) * 1992-07-21 1995-05-10 Knoll AG Utilisation de 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone dans le traitement de l'angine de poitrine
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
CA2339484A1 (fr) * 1998-08-03 2000-02-17 Robert A. O'brien Utilisation de pyridinones pour traiter les dysfonctionnements sexuels

Also Published As

Publication number Publication date
CA2319542A1 (fr) 1999-11-11
AU3780699A (en) 1999-11-23
BR9908716A (pt) 2000-11-21
JP2002537231A (ja) 2002-11-05
EP1079764A4 (fr) 2001-09-12
WO1999056666A8 (fr) 2000-08-10
WO1999056666A1 (fr) 1999-11-11
EP1079764A1 (fr) 2001-03-07
MXPA00010254A (es) 2002-08-06

Similar Documents

Publication Publication Date Title
US5236904A (en) Erection-inducing methods and compositions
JP2002087957A (ja) ヒトの性的応答を調節するための方法及び製剤
US6132757A (en) Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) Use of cilostazol for treatment of sexual dysfunction
CA2319542C (fr) Traitement des troubles de la sexualite chez certains groupes de patients
US20230255940A1 (en) Oxymetazoline for the treatment of ano-rectal disorders
US6194433B1 (en) Sexual dysfunction in females
US6110489A (en) Use of quinolines and quinolones to treat male erectile dysfunction
US6132753A (en) Treatment of sexual dysfunction in certain patient groups
US6541487B1 (en) PDE III inhibitors for treating sexual dysfunction
US6303135B1 (en) Use of quinolines and quinolones to treat male erectile dysfunction
US6426084B1 (en) Treatment of sexual dysfunction in certain patient groups
AU2002300509B2 (en) The Treatment of Sexual Dysfunction in Certain Patient Groups
US20020147217A1 (en) The treatment of sexual dysfunction with enantiomers
CA2435876A1 (fr) Traitement de troubles sexuels et de maladie cardio-vasculaire avec des enantiomeres quinolinone
US20050260253A1 (en) Transmucosal gel formulations

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed